NeuroSense Therapeutics (NRSN) Current Assets (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Current Assets of $778000.0 for Q4 2025, down 50.0% sequentially from $1.6 million in Q2 2025, and down 82.33% YoY from $4.4 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Current Assets (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Current Assets for 6 years, with the latest figure at $778000.0 in Q4 2025.
- Quarterly Current Assets fell 82.33% year-over-year to $778000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $778000.0 (down 82.33% YoY) and the FY2025 annual result came in at $778000.0, down 82.33% from the prior year.
- Current Assets declined to $778000.0 in Q4 2025 per NRSN's latest filing, from $1.6 million in the prior quarter.
- Over five years, Current Assets peaked at $7.6 billion in Q2 2023 and troughed at $778000.0 in Q4 2025.
- A 5-year average of $509.1 million and a median of $5.0 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets surged 67992.58% in 2023, then sank 99.98% in 2024.
- Over 5 years, Current Assets stood at $11.4 million in 2021, then tumbled by 35.32% to $7.4 million in 2022, then tumbled by 60.49% to $2.9 million in 2023, then soared by 50.96% to $4.4 million in 2024, then slumped by 82.33% to $778000.0 in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $778000.0, $1.6 million, and $4.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 778,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 778,000.00 |
| Jun 30, 2025 | 1.56 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | 785,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | 2.92 Mn |
| Sep 30, 2023 | 5.11 Mn |
| Jun 30, 2023 | 7.56 Bn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 7.38 Mn |
| Sep 30, 2022 | 8.89 Mn |
| Jun 30, 2022 | 11.10 Mn |
| Mar 31, 2022 | 14.03 Mn |
| Dec 31, 2021 | 11.41 Mn |
| Dec 31, 2020 | 766,000.00 |